CYTOKINETICS INC (CYTK) Stock Price, Quote, News and Overview
NASDAQ:CYTK - Nasdaq - US23282W6057 - Common Stock - Currency: USD
CYTK Quote, Performance and Key Statistics
CYTOKINETICS INC
NASDAQ:CYTK (2/5/2025, 10:37:27 AM)
50.33
+1.13 (+2.3%)
The current stock price of CYTK is 50.33 USD. In the past month the price decreased by -0.32%. In the past year, price decreased by -36.05%.
CYTK Latest News, Press Releases and Analysis
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2025 it...
Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Cytokinetics, Inc. (NASDAQ:...
Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program
Total of $100,000 Awarded to Five Patient Advocacy Organizationsto Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif., Jan. 30,...
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.
Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF (Assessment of...
CYTK Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.08 | 341.15B | ||
| AMGN | AMGEN INC | 15.38 | 163.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 956.71 | 125.65B | ||
| GILD | GILEAD SCIENCES INC | 22.46 | 124.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.6 | 78.25B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.68B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.59B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.57B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.30B | ||
| NTRA | NATERA INC | N/A | 23.37B | ||
| BIIB | BIOGEN INC | 8.93 | 21.26B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.63 | 15.89B |
Related stock screener links
About CYTK
Company Profile
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The company is headquartered in South San Francisco, California and currently employs 423 full-time employees. The company went IPO on 2004-04-29. The firm specializes in muscle biology and the mechanics of muscle performance. The company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.
Company Info
CYTOKINETICS INC
350 Oyster Point Boulevard
South San Francisco CALIFORNIA 94080 US
CEO: Robert I. Blum
Employees: 423
Company Website: https://cytokinetics.com/
Investor Relations: https://ir.cytokinetics.com
Phone: 16506243000
CYTK FAQ
What is the stock price of CYTK?
The current stock price of CYTK is 50.33 USD.
What is the symbol for CYTOKINETICS INC stock?
The exchange symbol of CYTOKINETICS INC is CYTK and it is listed on the Nasdaq exchange.
On which exchange is CYTK stock listed?
CYTK stock is listed on the Nasdaq exchange.
Is CYTK a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for CYTK, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of CYTK.
Does CYTK stock pay dividends?
CYTK does not pay a dividend.
When does CYTK stock report earnings?
CYTK will report earnings on 2025-02-20, after the market close.
What is the Price/Earnings (PE) ratio of CYTK?
CYTK does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.38).
What is the Short Interest ratio of CYTK stock?
The outstanding short interest for CYTK is 12.13% of its float.
CYTK Technical Analysis
CYTK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CYTK. CYTK has a bad profitability rating. Also its financial health evaluation is rather negative.
CYTK Financial Highlights
Over the last trailing twelve months CYTK reported a non-GAAP Earnings per Share(EPS) of -5.38. The EPS decreased by 2.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.14% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CYTK Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to CYTK. The Buy consensus is the average rating of analysts ratings from 24 analysts.
For the next year, analysts expect an EPS growth of 1.94% and a revenue growth -66.75% for CYTK